Longitudinal metagenomic study shows no significant gut microbiome disruption in dogs treated for leishmaniosis
Our study on the effects of meglumine antimoniate and allopurinol on the faecal microbiome of dogs with leishmaniosis has been published in Animal Microbiome. It is the first longitudinal metagenomic evaluation of the gut microbiota in Leishmania-infected dogs under standard treatment.
Ten privately owned dogs from Spain, Portugal and Italy were sampled three times: before treatment, after one month of combined therapy, and after six months of allopurinol alone. The samples were analysed by shotgun metagenomic sequencing.
Overall microbiome composition remained stable, with no significant changes in diversity. The most abundant genera were Prevotella, Collinsella, Blautia and Bacteroides, and differences between individual dogs explained more than half of the diversity observed. The standard protocol did not cause detectable microbiome impairment, which suggests the gut microbiome stays resilient during treatment.
The multicentre study involved the Hospital Clínic Veterinari (UAB, Spain), CIISA-FMV (University of Lisbon, Portugal) and the University of Naples Federico II (Italy). It was supported by Nestlé Purina PetCare Europe; the design, execution and interpretation of the research were independent.
Questions about this news? Write to info@nano1health.com.